Danaher Corporation - DHR STOCK NEWS

Danaher Corporation (NYSE: DHR) announced that its Executive Vice President and CFO, Matt McGrew, will present at the Jefferies Healthcare Conference on June 2, 2021, at 1:00 p.m. ET. The presentation will be available via a live webcast on Danaher's official website. Danaher is a leader in science and technology, focusing on solving complex challenges and improving global quality of life. With over 69,000 associates, Danaher operates more than 20 companies across health care, environmental, and applied end-markets.

Danaher Corporation (NYSE: DHR) announced the appointment of A. Shane Sanders to its Board of Directors and Audit Committee, increasing the board size to thirteen members. Sanders, currently Senior Vice President of Business Transformation at Verizon Communications Inc. (NYSE: VZ), has extensive experience in corporate finance, having served in leadership roles since joining Verizon in 1997. His qualifications include a B.S. in Accounting and an M.B.A. His appointment is expected to enhance Danaher's leadership and support its goal of building long-term shareholder value.

Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.21 per share on its common stock, payable on July 30, 2021, to shareholders on record as of June 25, 2021. Additionally, the company announced dividends of $11.875 per share for its 4.75% Series A Mandatory Convertible Preferred Stock and $12.50 per share for its 5.00% Series B Mandatory Convertible Preferred Stock, both payable on July 15, 2021, with record dates of June 30, 2021.

Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, presenting at the Bank of America Healthcare Conference on May 11, 2021, at 2:00 p.m. ET. The presentation will be webcast live on Danaher's official website. Danaher is recognized as a global leader in science and technology, focusing on solving complex challenges across health care, environmental, and applied end-markets. With over 69,000 employees, Danaher operates more than 20 companies unified by the Danaher Business System, dedicated to enhancing quality of life worldwide.

Danaher Corporation (NYSE: DHR) has established a Scientific Advisory Board to bolster its innovation and investment strategies. The Board comprises renowned scientists, including two Nobel laureates, who will aid in assessing M&A opportunities and guiding early-stage investments. Their role involves collaborating with Danaher’s leadership to enhance scientific innovations essential for global health. CEO Rainer Blair emphasized the Board's key role in aligning Danaher’s scientific agenda with evolving healthcare needs. This strategic move aims to strengthen Danaher's competitive edge and accelerate advancements in health technologies.

Danaher Corporation (NYSE: DHR) reported robust Q1 2021 results, showcasing net earnings of $1.7 billion or $2.29 per diluted share, marking a 182.5% year-over-year increase. Revenues surged 58.0% to $6.9 billion, with 30.0% non-GAAP core revenue growth including Cytiva. Operating cash flow reached $1.9 billion, a 126.5% rise year-over-year. Looking ahead, Danaher expects mid-20% non-GAAP core revenue growth for Q2 and high-teens growth for the full year. CEO Rainer M. Blair highlighted strong market performance driven by contributions to COVID-19 related developments.

Danaher Corporation (NYSE: DHR) announced that its first quarter 2021 core revenue growth exceeded expectations, with total revenue growth at approximately 57.0% and non-GAAP core revenue growth including Cytiva at 29.0%. This strong performance was attributed to significant growth in the Life Sciences and Diagnostics segments. The company will discuss these results in its earnings conference call on April 22, 2021. The non-GAAP measures mentioned will aid investors in understanding underlying growth trends.

Danaher Corporation (NYSE: DHR) is scheduled to host its first-quarter 2021 earnings conference call on April 22, 2021, at 8:00 a.m. ET. The call will be available on Danaher’s website, along with a slide presentation. A replay of the call will be accessible until May 6, 2021. Investors can join the call by dialing 866-503-8675 in the U.S. or +1 786-815-8792 outside the U.S. The earnings press release and related materials will be available on their website by 6:00 a.m. ET on the day of the call.

Beckman Coulter announced that its Access SARS-CoV-2 IgG II antibody assay has received U.S. Emergency Use Authorization (EUA) from the FDA. This semi-quantitative test measures antibody levels post-SARS-CoV-2 infection, delivering results that will help clinicians monitor patients' immune responses. The assay boasts a 99.9% specificity and 98.9% sensitivity. Available in the U.S. and countries accepting the CE Mark, it integrates into existing workflows and can process up to 4,800 samples per day using the DxI 800 analyzer. Beckman Coulter aims to enhance COVID-19 diagnostics.